Wireless Capsule Endoscopy and Wireless Gastrointestinal Motility Monitoring System

Coverage Summary

UnitedHealthcare Medicare Advantage medical policy MMP036.13 addresses the use and coverage of Wireless Capsule Endoscopy (WCE) and Wireless Gastrointestinal Motility Monitoring Systems (Wireless Motility Capsule / SmartPill). The policy covers esophageal capsule endoscopy, small-bowel capsule endoscopy, and the SmartPill wireless motility capsule for specified indications, and it references applicable Medicare Local Coverage Determinations (LCDs) and Local Coverage Articles (LCAs) by MAC jurisdiction where required. The policy effective date is April 1, 2025.

Covered indications summarized: esophageal WCE is considered medically necessary when the patient has portal hypertension requiring immediate evaluation of esophageal varices and conventional endoscopy is prohibited by the patient’s current medical condition; small-bowel WCE is medically necessary for either initial diagnosis of suspected Crohn’s disease when conventional tests (SBFT and upper and lower endoscopy) are non-diagnostic, or for obscure small-bowel bleeding with documented continuous blood loss and anemia when the bleeding site was not identified by colonoscopy/endoscopy, radiographic exams have failed to reveal a source, or intraoperative enteroscopy is being considered; the Wireless Motility Capsule (SmartPill) is medically necessary when used by a trained gastroenterologist after basic investigations (including endoscopy) fail to establish a diagnosis and is used to evaluate suspected gastroparesis or to evaluate colonic transit in chronic idiopathic constipation lasting >6 months.

The policy notes exclusions and contraindications (e.g., colorectal cancer screening, confirmation of lesions reachable by standard endoscopes, patients with radiographic evidence of obstruction or significant small-bowel narrowing, implanted electromagnetic devices, use of FDA non-approved devices, and procedures performed by clinicians not trained in endoscopy) and explicitly states that patency capsule testing is not reasonable and necessary per the policy. Where applicable, providers must comply with LCDs/LCAs listed by MAC jurisdiction prior to authorization and follow member-specific benefit determinations.

Medical Necessity Criteria

Wireless capsule endoscopy of the esophagus - Medically necessary

Reasonable and necessary when ALL of the following are met:

ALL of the following

Patient diagnosed with portal hypertension who requires immediate evaluation of esophageal varices
The esophageal capsule endoscopy is performed in lieu of conventional endoscopy because the provider who would perform the endoscopy has determined that the patient's current medical condition prohibits a conventional endoscopy
Performance of esophageal capsule endoscopy for any other reason is not reasonable and necessary.

Wireless capsule endoscopy of the small bowel - Medically necessary

Reasonable and necessary when ANY one of the following is met:

ANY of the following

Not Reasonable and Necessary / Contraindications

Wireless capsule endoscopy - Not reasonable and necessary (contraindications / exclusions)

Wireless capsule endoscopy is not reasonable and necessary in any of the following situations:

ANY of the following

Colorectal cancer screening
Confirmation of lesions of pathology normally within the reach of upper and lower endoscopes (proximal to the ligament of Treitz, or distal to the ileum)
Patients in whom a radiological exam of the small bowel has confirmed an intestinal blockage, a significantly narrow small bowel, or an abnormal connection between the bowel and another organ; an x-ray exam of the small bowel should be done if there is concern that it may be too narrow for the camera
Patients with a cardiac pacemaker, or other implanted electromagnetic devices

Coding

Covered / referenced CPT codes for WCECPTCovered

91110	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus through ileum, with interpretation and report.
91111	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with interpretation and report.
91299	Unlisted diagnostic gastroenterology procedure.

Covered / referenced CPT code for Wireless Motility MonitoringCPTCovered

91112

Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule, with interpretation and report.

Associated ICD-10 diagnosis codesICD-10

A18.32	Tuberculous enteritis.
A18.39	Retroperitoneal tuberculosis.
A18.83	Tuberculosis of digestive tract organs, not elsewhere classified.
C17.0	Malignant neoplasm of duodenum.
C17.1	Malignant neoplasm of jejunum.
C17.2	Malignant neoplasm of ileum.
C17.3	Meckel's diverticulum, malignant.
C17.8	Malignant neoplasm of overlapping sites of small intestine.
C17.9	Malignant neoplasm of small intestine, unspecified.
C49.A3	Gastrointestinal stromal tumor of small intestine.

1–10 of 57

1/6

FDA product / device informationmixed

SmartPill	Wireless Gastrointestinal Motility Monitoring System (trade name SmartPill®) — ingestible capsule that records pH, temperature, and pressure to estimate regional and total GI motility; FDA approved to evaluate suspected delayed gastric emptying and colonic transit time in chronic idiopathic constipation.
WCE capsules	Disposable wireless capsule endoscopy devices containing light source, miniature color video camera, battery, antenna, and transmitter — designed for visualization of esophageal and small bowel mucosa; disposable and excreted naturally.
Patency Capsule	Patency capsule testing is noted as not reasonable and necessary due to insufficient peer-reviewed literature and reported cases of obstruction requiring urgent intervention.
Precautions	WCE contraindications include known or suspected GI obstruction, strictures, fistulas, presence of implanted electromagnetic devices (e.g., pacemaker) unless determined safe, and use of non–FDA-approved devices.
Operator requirements	Devices (WCE and WMC) should be used and interpreted by gastroenterologists trained in endoscopy/motility interpretation.
Medication discontinuation	For WMC (SmartPill) testing, patient should discontinue medications that affect the GI tract prior to study.

Provider Actions & Authorization

Prior Authorization

Reference to LCDs/LCAs

Where applicable, comply with Local Coverage Determinations (LCDs) and Local Coverage Articles (LCAs) for wireless capsule endoscopy and wireless gastrointestinal motility monitoring systems prior to authorization. Refer to the policy table listing LCDs/LCAs by MAC jurisdiction (for example: CGS, First Coast, NGS, Noridian, Novitas, Palmetto, WPS) and the specific LCD/LCA identifiers provided in the policy.

Documentation Required

Clinical documentation for esophageal WCE

Document portal hypertension (eg, diagnosis codes I85.00 or I85.01 and K76.6) and that conventional endoscopy cannot be performed because the patient's current medical condition prohibits it. Include the clinical justification that the esophageal capsule endoscopy is being performed in lieu of conventional endoscopy for this reason.

Background & Evidence Summary

Wireless capsule endoscopy (WCE) uses an ingestible disposable video capsule containing a light source, color camera, battery, antenna, and transmitter; the capsule transmits images to an external wearable data recorder for later download and physician interpretation and is designed to be excreted naturally. The SmartPill (Wireless Motility Capsule, WMC) is an ingestible capsule that measures pH, temperature, and pressure to estimate regional and whole-gut transit times and pressure patterns; it is FDA-cleared for evaluation of suspected delayed gastric emptying and for colonic transit assessment in chronic idiopathic constipation.

Safety and retention concerns: the literature and assessments note capsule retention as the most important complication of WCE and that patients with bowel obstruction should not receive WCE; patency capsule testing has limited and low-quality evidence, potential for false results, and reports of patency capsule–related obstruction, and UnitedHealthcare’s policy states patency capsule testing is not reasonable and necessary. Meta-analyses and systematic reviews report pooled performance measures (e.g., pooled detection rate ~ 59%, pooled completion rate ~ 89.6%, pooled retention rate ~ 2%) across capsule types, while device- and indication-specific studies (including magnetically guided esophageal capsule studies) have demonstrated high sensitivity and specificity for some esophageal indications but also note limitations and that WCE does not universally replace EGD.

Practice guidelines and evidence assessments: professional guidelines (AGA, ACG, ASGE) and technology assessments (Hayes, NICE) acknowledge WCE and WMC as useful tools in specified clinical contexts—e.g., ACG gives a conditional (low-grade) recommendation that WMC may be an alternative to scintigraphic gastric emptying testing for gastroparesis—while Hayes HTAs conclude the overall evidence quality for WMC guiding management is low to very low, and NICE recommended use with special arrangements due to uncertainty about clinical benefit. The policy also references FDA product information and 510(k) clearance summaries for the SmartPill supporting its intended uses and measurement outputs.

Study	Finding
Jiang et al. (2024)
ds-MCE sensitivity 97.5% and specificity 97.8% for detecting esophagogastric varices versus EGD; high diagnostic accuracy (≈96% for high-risk varices) and no serious adverse events with ds-MCE in multicenter prospective study (n=607)
Cortegoso Valdivia et al. (2022)
Systematic review/meta-analysis (328 studies, 86,930 patients) reported pooled detection rate 59%, completion rate 89.6%, and pooled capsule retention rate 2% across capsule types
Hayes reviews
Hayes evolving evidence and HTAs: limited/variable evidence supporting routine use of patency capsule (concerns re: false-negatives/positives, retention risk); CE/WCE evidence moderate for diagnostic yield but variable quality; WMC evidence overall very low quality for effectiveness in gastroparesis though reasonably safe
McCarty et al. (2017)
Systematic review/meta-analysis (17 studies, 1328 adults) reported WCE diagnostic accuracy for esophageal varices 90%; pooled sensitivity 83% and specificity 85% (grading analyses also reported)
Eriksson et al. (2023)
Single-center retrospective (n=48): longer WGTT/CTT associated with suboptimal anti-reflux surgery outcomes; authors recommend RCTs and larger studies
Hayes HTA (2023)
Reviewed 9 studies of SmartPill/WMC; concluded evidence very low quality for effectiveness in diagnosing/guiding gastroparesis management though device reasonably safe
Sangnes et al. (2020)
Prospective single-center (n=72, analysis n=66): WMC correlated with GES (r=0.74); sensitivity 0.92 and specificity 0.73 at GET cutoff 300 min; at 385 min specificity improved to 0.83 without loss of sensitivity
Lee et al. (2019)
Multicenter prospective cohort (n=167, analysis n=154): WMC detected delayed GE more frequently than GES (34.6% vs 24.5%); overall agreement 75.7%; WMC identified extra-gastric transit abnormalities
ACG guideline (2022)
ACG conditional recommendation (low GRADE) that WMC may be an alternative to scintigraphic gastric emptying for evaluation of gastroparesis
AGA update (2022)
AGA recommends meal-based scintigraphy as first-line over WMC for physiologic assessment and notes common improper scintigraphy can lead to misdiagnosis
NICE IPG502 (2014)
NICE: no major safety concerns for wireless capsule motility assessment but uncertainty about clinical benefits and patient selection; recommended only with special arrangements for governance, consent, and audit/research

Medicare LCDs / LCAs

Name	Number/Identifier	Type	Notes
Wireless Capsule Endoscopy (WCE)
various by MAC (see policy table)
LCD
Local Coverage Determinations (various LCDs/LCAs by MAC jurisdictions listed in policy table; compliance required where applicable)
Wireless Gastrointestinal Motility Monitoring Systems
L33455 (Palmetto) and others listed
LCD
Palmetto L33455 (Wireless Gastrointestinal Motility Monitoring Systems) and associated LCA(s); refer to MAC table for jurisdiction-specific contractor names and LCD listings

Revision History

04/01/2025Summary of ChangesLatest

Updated Clinical Evidence and References sections to reflect the most current information; archived prior policy version MMP036.12. Change was to supporting information only (not material).